Department of Neurology, State University of Medicine and Pharmacy “Nicolae Testemiţanu”, Chişinău, Republic of MoldovaIntroduction: Myasthenia Gravis (MG) in the elderly is defined as onset after the age of 50 years. The incidence of late-onset MG without thymoma has been increasing in the last 20 years, in the USA and Europe. The increase is mainly found in patients over the age of 50 years. Recent data indicate that MG may still be substantially underdiagnosed in very old people (70 years). Purpose and objectives: To study the clinical features and the course of MG in elderly patients by performing a clinical trial and reviewing the medical literature. Material and methods: The clinical trial is based on 14 patients, older than 50 years ...
Objective Myasthenia gravis (MG) is classified as early-onset MG (EOMG; age at onset ≤49 years), lat...
Background: Myasthenia gravis is a potentially serious but treatable muscle disease caused by autoan...
Background: We present the findings from the largest hospital-based studies on myasthenia gravis fr...
The prevalence of myasthenia gravis is 10-24 cases per 100, 000 population. The debut of the disease...
To describe the characteristics of patients with very-late-onset myasthenia gravis (MG). This observ...
[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG)....
To evaluate clinical characteristics and outcome of myasthenia gravis (MG) in aged patients (>60yrs)...
To evaluate clinical characteristics and outcome of myasthenia gravis (MG) in aged patients (>60 yrs...
IntroductionIn this study, we aim to evaluate the treatment responses and prognostic characteristics...
<div><p>Background and Purpose</p><p>Myasthenia gravis (MG) is often categorized into thymoma-associ...
Introduction: The reported prevalence of myasthenia gravis ranges between 5 and 24 cases per 100,000...
Objective: The continuous increase in the number of patients presenting with late-onset myasthenia g...
Introduction: Myasthenia gravis (MG) is the most common acquired autoimmune disorder of neuromuscula...
Myasthenia gravis (MG) is a disorder of the neuromuscular junction that can deteriorate into myasthe...
Myasthenia gravis is probably commoner than previously suspected, the annual incidence being nearer ...
Objective Myasthenia gravis (MG) is classified as early-onset MG (EOMG; age at onset ≤49 years), lat...
Background: Myasthenia gravis is a potentially serious but treatable muscle disease caused by autoan...
Background: We present the findings from the largest hospital-based studies on myasthenia gravis fr...
The prevalence of myasthenia gravis is 10-24 cases per 100, 000 population. The debut of the disease...
To describe the characteristics of patients with very-late-onset myasthenia gravis (MG). This observ...
[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG)....
To evaluate clinical characteristics and outcome of myasthenia gravis (MG) in aged patients (>60yrs)...
To evaluate clinical characteristics and outcome of myasthenia gravis (MG) in aged patients (>60 yrs...
IntroductionIn this study, we aim to evaluate the treatment responses and prognostic characteristics...
<div><p>Background and Purpose</p><p>Myasthenia gravis (MG) is often categorized into thymoma-associ...
Introduction: The reported prevalence of myasthenia gravis ranges between 5 and 24 cases per 100,000...
Objective: The continuous increase in the number of patients presenting with late-onset myasthenia g...
Introduction: Myasthenia gravis (MG) is the most common acquired autoimmune disorder of neuromuscula...
Myasthenia gravis (MG) is a disorder of the neuromuscular junction that can deteriorate into myasthe...
Myasthenia gravis is probably commoner than previously suspected, the annual incidence being nearer ...
Objective Myasthenia gravis (MG) is classified as early-onset MG (EOMG; age at onset ≤49 years), lat...
Background: Myasthenia gravis is a potentially serious but treatable muscle disease caused by autoan...
Background: We present the findings from the largest hospital-based studies on myasthenia gravis fr...